Effect and Safety of Liraglutide 3.0 mg in Subjects With Overweight or Obesity and Type 2 Diabetes Mellitus Treated With Basal Insulin
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 23 Sep 2017
At a glance
- Drugs Liraglutide (Primary)
- Indications Obesity; Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms SCALE™ Insulin
- Sponsors Novo Nordisk
- 23 Aug 2017 Planned End Date changed from 24 Sep 2018 to 25 Sep 2018.
- 23 Aug 2017 Status changed from recruiting to active, no longer recruiting.
- 10 Jun 2017 Biomarkers information updated